Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2017 Jul 25;61(8):e01094-17.
doi: 10.1128/AAC.01094-17. Print 2017 Aug.

Use of β-Lactam/β-Lactamase Inhibitors for Extended-Spectrum-β-Lactamase Infections: Defining the Right Patient Population

Pranita D Tamma  1 , Maria Virginia Villegas  2
Affiliations
Observational Study

Use of β-Lactam/β-Lactamase Inhibitors for Extended-Spectrum-β-Lactamase Infections: Defining the Right Patient Population

Pranita D Tamma et al. Antimicrob Agents Chemother. .

Abstract

In a multicenter, multinational observational study that included neutropenic patients with bloodstream infections by extended-spectrum-β-lactamase-producing species, Gudiol et al. (Antimicrob. Agents Chemother. 61:e00164-17, 2017, https://doi.org/10.1128/AAC.00164-17) demonstrated that β-lactam/β-lactamase inhibitors are effective treatment options. A review of this work, however, reminds us that some lingering questions remain for specific high-risk subgroups.

Keywords: ESBL; Gram negative; MDRGN; meropenem; piperacillin-tazobactam.

PubMed Disclaimer

References

    1. Thomson KS, Moland ES. 2001. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum β-lactamase-producing Enterobacteriaceae. 2001. Antimicrob Agents Chemother 45:3548–3554. doi:10.1128/AAC.45.12.3548-3554.2001. - DOI - PMC - PubMed
    1. Burgess DS, Hall RG II. 2004. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum β-lactamase and non-ESBL producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 49:41–46. doi:10.1016/j.diagmicrobio.2003.11.007. - DOI - PubMed
    1. Docobo-Pérez F, López-Cerero L, López-Rojas R, Egea P, Domínguez-Herrera J, Rodríguez-Baño J, Pascual A, Pachón J. 2013. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model. Antimicrob Agents Chemother 57:2109–2113. doi:10.1128/AAC.02190-12. - DOI - PMC - PubMed
    1. Harada Y, Morinaga Y, Kaku N, Nakamura S, Uno N, Hasegawa H, Izumikawa K, Kohno S, Yanagihara K. 2014. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae. Clin Microbiol Infect 20:O831–O839. doi:10.1111/1469-0691.12677. - DOI - PubMed
    1. Woodford N, Carattoli A, Karisik E, Underwood A, Ellington MJ, Livermore DM. 2009. Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. Antimicrob Agents Chemother 53:4472–4482. doi:10.1128/AAC.00688-09. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources